Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 8/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.41 |
| ▸ | VDR | P11473 | 2/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.39 |
| ▸ | CNR2 | P34972 | 4/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1481890 | 0.91 | NR1H4 (0.49) | NR1H4ALOX5VDRCYP3A4CYP2D6 | |
| SCHEMBL1482100 | 0.82 | NR1H4 (0.50) | NR1H4ALOX5VDRCNR2CYP3A4 | |
| SCHEMBL1482697 | 0.82 | NR1H4 (0.50) | NR1H4ALOX5VDRCNR2CYP3A4 | |
| SCHEMBL1483132 | 0.81 | NR1H4 (0.49) | NR1H4ALOX5VDRCNR2CYP3A4 | |
| SCHEMBL1482662 | 0.81 | NR1H4 (0.51) | NR1H4ALOX5VDRCNR2MAPT | |
| SCHEMBL1483183 | 0.81 | NR1H4 (0.42) | NR1H4CNR1BACE1CYP3A4CYP2D6 | |
| SCHEMBL1482606 | 0.81 | NR1H4 (0.49) | NR1H4ALOX5VDRCYP3A4CYP2D6 | |
| SCHEMBL1482477 | 0.80 | NR1H4 (0.49) | NR1H4ALOX5VDRCYP3A4CYP2D6 | |
| SCHEMBL1482639 | 0.80 | NR1H4 (0.49) | NR1H4ALOX5VDRP2RX3CNR2 | |
| SCHEMBL1482722 | 0.80 | NR1H4 (0.49) | NR1H4ALOX5VDRMAPTCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309581-B2 | Benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-11-13 | — | — | US | disclosed |
| EP-2483247-A1 | NEW BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS | F. Hoffmann-La Roche AG (CH) | 2012-08-08 | — | — | EP | disclosed |
| WO-2011039130-A1 | NEW BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-07 | — | — | WO | disclosed |
| US-20110077273-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077273-A1 | NEW BENZIMIDAZOLE DERIVATIVES | BRI3BP, CYP3A4, RB1 | NR1H4 776/4885ALOX5 3919/4885VDR 1436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.